Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?

This publication has 53 references indexed in Scilit:

• Influence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS)
  Circulation, 1998
• Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease
  Current Opinion in Lipidology, 1995
• Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels
  Circulation, 1995
• Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
  The Lancet, 1995
• Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the framingham offspring study
  The American Journal of Medicine, 1991
• High density lipoprotein cholesterol and mortality. The Framingham Heart Study.
  Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1988
• Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
  New England Journal of Medicine, 1987
• High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial.
  Circulation, 1986
• Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
  JAMA, 1986
• Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded?
  JAMA, 1986